<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE SOLUTION- hydrocodone bitartrate and chlorpheniramine maleate solution </strong><br>Tris Pharma Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold"><span class="Bold">These highlights do not include all the information needed to use Hydrocodone Bitartrate and Chlorpheniramine Maleate Oral Solution safely and effectively. See full prescribing information for Hydrocodone Bitartrate and Chlorpheniramine Maleate Oral Solution. CII<br><br>Hydrocodone Bitartrate and Chlorpheniramine Maleate Solution, for oral use <br>Initial U.S. Approval: [1987]</span></span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Hydrocodone bitartrate and chlorpheniramine maleate oral solution is a combination of hydrocodone bitartrate, an antitussive, and chlorpheniramine maleate, a histamine-1 (H<span class="Sub">1</span>) receptor antagonist, indicated for relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and symptoms associated with upper respiratory allergies or a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> (<span class="Bold"><a href="#LINK_5cfbae1b-99f3-4687-a716-dce5aa3d4673">1.1</a></span>) </p>
<p class="Highlighta"><span class="Underline">Limitations of Use:</span> </p>
<p class="Highlighta">Not indicated for pediatric patients under 18 years of age (<span class="Bold"><a href="#LINK_5cfbae1b-99f3-4687-a716-dce5aa3d4673">1.1</a></span>) </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li><p class="Highlighta">For Oral Use Only (<span class="Bold"><a href="#LINK_ef52949f-e4dd-4c45-b7ab-fbbd280a9d85">2</a></span>) </p></li>
<li><p class="Highlighta">Adults 18 years of age and older: 5 mL every 4 to 6 hours as needed, not to exceed 4 doses (20 mL) in 24 hours (<span class="Bold"><a href="#LINK_ef52949f-e4dd-4c45-b7ab-fbbd280a9d85">2</a></span>) </p></li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each 5 mL of hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution contains: hydrocodone bitartrate, USP, 5 mg; and pseudoephedrine hydrochloride, USP, 60 mg. (<span class="Bold"><a href="#LINK_548dd1ea-2a97-4df9-b0bb-b24380dc2cbf">3</a></span>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<ul class="Disc"><li><p class="Highlighta">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, chlorpheniramine, or any of the inactive ingredients of hydrocodone bitartrate and chlorpheniramine maleate oral solution (<span class="Bold"><a href="#LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">4</a></span>) </p></li></ul>
<ul class="Disc">
<li><p class="Highlighta">Patients receiving monoamine oxidase inhibitor (MAOI) therapy or within 14 days of stopping such therapy (<span class="Bold"><a href="#LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">4</a></span>) </p></li>
<li><p class="Highlighta">Patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or severe <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (<span class="Bold"><a href="#LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">4</a></span>) </p></li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li><p class="Highlighta">Dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>: Use with caution. (<span class="Bold"><a href="#LINK_58123411-0f53-420e-b00f-3638667874ad">5.1</a></span>)  </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>: Prescribe with caution that is appropriate to the use of other opioids. (<span class="Bold"><a href="#LINK_8bda7078-e860-4780-b213-12ea2ac673fe">5.2</a></span>)  </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>: Avoid in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intra-cranial lesions, or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. (<span class="Bold"><a href="#LINK_9347e0b3-f4e0-485f-8e37-6386926e46fe">5.3</a></span>)  </p></li>
<li><p class="Highlighta">Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating machinery. (<span class="Bold"><a href="#LINK_496fdcbc-2473-4a5b-8561-245dfe45c09a">5.4</a></span>)  </p></li>
<li><p class="Highlighta">Acute abdominal conditions: Use with caution in patients with acute abdominal conditions. (<span class="Bold"><a href="#LINK_21855ad0-7043-4e5a-9840-91abf3930301">5.5</a></span>)  </p></li>
<li><p class="Highlighta">Coexisting conditions: Use with caution in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease, Addison’s disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<span class="Bold"><a href="#LINK_0c062d2f-49ca-44f6-a30d-76824986a1bb">5.10</a></span>)  </p></li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions were sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>; blurred, double, or other <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, facial <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (<span class="Bold"><a href="#LINK_eb8a0e30-63ca-4ced-84b8-8c5655f401dc">6</a></span>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc., at 732-940-0358 or FDA at 1-800-FDA-1088 or </span><span class="Bold">www.fda.gov/medwatch</span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<ul class="Disc"><li><p class="Highlighta">Opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants: Avoid use with hydrocodone bitartrate and chlorpheniramine maleate; may cause additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> (<span class="Bold"><a href="#LINK_cf1ca2b1-a77b-44f6-b982-02872e9bbfb2">7.1</a></span>) </p></li></ul>
<ul class="Disc">
<li><p class="Highlighta">MAOIs or tricyclic antidepressants: Do not use. May increase the effect of either the antidepressant or hydrocodone (<span class="Bold"><a href="#LINK_283b0d0f-f10c-42b1-ab80-284125dd09f2">7.2</a></span>) </p></li>
<li><p class="Highlighta">Anticholinergic drugs: Use with caution. Additive adverse effects resulting from cholinergic blockade (e.g., <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">xerostomia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>) may occur (<span class="Bold"><a href="#LINK_1538533e-2525-4407-8e5f-eae7ad77fc97">7.3</a></span>) </p></li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Use with caution (<span class="Bold"><a href="#LINK_ece0ac25-8b59-4f27-9721-f07e8655c78d">8.6</a></span>) </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Use with caution (<span class="Bold"><a href="#LINK_ada8f944-eacd-4838-a32f-c2bceadaad81">8.7</a></span>) </p></li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> and Upper Respiratory <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Symptoms</a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">​</span>2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults 18 Years of Age and Older</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Activities Requiring Mental Alertness</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Acute Abdominal Conditions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Co-administration with Anticholinergics</a></h2>
<h2><a href="#section-5.7" class="toc">5.7  Co-administration with MAOIs or Tricyclic Antidepressants</a></h2>
<h2><a href="#section-5.8" class="toc">5.8  Dosing</a></h2>
<h2><a href="#section-5.9" class="toc">5.9  Coexisting Conditions</a></h2>
<h2><a href="#section-5.10" class="toc">5.10  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 MAOIs and Tricyclic Antidepressants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticholinergic Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1  Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2  Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3  <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Overdosage</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Dosing</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Concomitant Use of Alcohol and Other Central Nervous System Depressants</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Activities Requiring Mental Alertness</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6 MAOIs</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_f3bb862a-af1e-4fbd-99fb-9c45bff83072"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5cfbae1b-99f3-4687-a716-dce5aa3d4673"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> and Upper Respiratory <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Symptoms</h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution is indicated for relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and symptoms associated with upper respiratory allergies or a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> in adults 18 years of age and older.</p>
<p><span class="Underline">Important Limitations of Use</span></p>
<p>Not indicated for pediatric patients under 18 years of age <span class="Italics">[see Use in Specific Populations <span class="Bold">(<a href="#LINK_f9b81963-404c-460a-8520-dda49e563fd9">8.4</a>)</span>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_ef52949f-e4dd-4c45-b7ab-fbbd280a9d85"></a><a name="section-2"></a><p></p>
<h1>
<span class="Bold">​</span>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Administer hydrocodone bitartrate and chlorpheniramine maleate oral solution by the oral route only. Measure hydrocodone bitartrate and chlorpheniramine maleate oral solution with an accurate milliliter measuring device. Do not use a household teaspoon to measure the dose <span class="Italics">[see Warnings and Precautions <span class="Bold">(<a href="#LINK_f9b81963-404c-460a-8520-dda49e563fd9">5.8</a></span><span class="Bold">)</span>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8d6e64a2-6758-495d-97dd-e4b4a5ff5d22"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults 18 Years of Age and Older</h2>
<p class="First">5 mL every 4 to 6 hours as needed, not to exceed 4 doses (20 mL) in 24 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_548dd1ea-2a97-4df9-b0bb-b24380dc2cbf"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate is a clear, colorless to light yellow, grape-flavored liquid.</p>
<p>5 mL of hydrocodone bitartrate and chlorpheniramine maleate oral solution contains: hydrocodone bitartrate, USP, 5 mg and chlorpheniramine maleate, USP, 4 mg <span class="Italics">[see Description <span class="Bold">(<a href="#LINK_fbac5b4a-b11d-470f-9e1b-b21e8685d2d1">11</a></span><span class="Bold">)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution is contraindicated in: </p>
<ul class="Disc">
<li><p class="First">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, pseudoephedrine hydrochloride, or any of the inactive ingredients of Hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution. </p></li>
<li><p class="First">Patients receiving MAOI therapy or within 14 days of stopping such therapy <span class="Italics">[see <span class="Italics">Drug Interactions <span class="Bold">(<a href="#LINK_283b0d0f-f10c-42b1-ab80-284125dd09f2">7.2</a>)</span></span></span><span class="Italics">]</span>. </p></li>
</ul>
<ul class="Disc"><li><p class="First">Patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or severe <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. </p></li></ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_646f0c1a-88d4-4c02-8f2a-488fbf6356b0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_58123411-0f53-420e-b00f-3638667874ad"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Hydrocodone bitartrate, one of the active ingredients in hydrocodone bitartrate and chlorpheniramine maleate oral solution, produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by directly acting on brain stem respiratory centers. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of hydrocodone bitartrate in adults has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and the use of hydrocodone bitartrate in children less than 6 years of age has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Exercise caution when administering Hydrocodone bitartrate and chlorpheniramine maleate oral solution because of the potential for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, discontinue hydrocodone bitartrate and chlorpheniramine maleate oral solution and use naloxone hydrochloride when indicated to antagonize the effect and other supportive measures as necessary <span class="Italics">[see Overdosage </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8bda7078-e860-4780-b213-12ea2ac673fe"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of hydrocodone bitartrate and chlorpheniramine maleate oral solution. Prescribe and administer hydrocodone bitartrate and chlorpheniramine maleate with the same degree of caution appropriate to the use of other opioid drugs <span class="Italics">[see Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_251610c3-fcdb-4588-b05b-d5aa6d1c93fb">9.2</a></span></span></span><span class="Italics">, <span class="Bold"><span class="Italics"><a href="#LINK_b1188204-6e04-4c09-a4b1-d4c0b164e906">9.3</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9347e0b3-f4e0-485f-8e37-6386926e46fe"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of hydrocodone bitartrate and chlorpheniramine maleate oral solution should be avoided in these patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_496fdcbc-2473-4a5b-8561-245dfe45c09a"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Activities Requiring Mental Alertness</h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate, the active ingredients in hydrocodone bitartrate and chlorpheniramine maleate oral solution, may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of hydrocodone bitartrate and chlorpheniramine maleate oral solution. Concurrent use of hydrocodone bitartrate and chlorpheniramine maleate oral solution with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_21855ad0-7043-4e5a-9840-91abf3930301"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Acute Abdominal Conditions</h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution should be used with caution in patients with acute abdominal conditions since the administration of hydrocodone may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of other anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> <span class="Italics">[see Drug Interactions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_1538533e-2525-4407-8e5f-eae7ad77fc97">7.3</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0e960a6b-9598-4670-8585-ad95583a4642"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Co-administration with Anticholinergics</h2>
<p class="First">The concurrent use of anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. Exercise caution when using hydrocodone bitartrate and chlorpheniramine maleate oral solution in patients taking anticholinergic medications <span class="Italics">[see Drug Interactions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_1538533e-2525-4407-8e5f-eae7ad77fc97">7.3</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d22b5f39-568f-4f6d-b818-7f2a195ae08b"></a><a name="section-5.7"></a><p></p>
<h2>5.7  Co-administration with MAOIs or Tricyclic Antidepressants</h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution should not be used in patients receiving MAOI therapy or within 14 days of stopping such therapy. The use of MAOIs or tricyclic antidepressants with hydrocodone bitartrate, one of the active ingredients in hydrocodone bitartrate and chlorpheniramine maleate oral solution, may increase the effect of either the antidepressant or hydrocodone [<span class="Italics">see Contraindications </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">4</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics"> and Drug Interactions <span class="Bold">(<a href="#LINK_283b0d0f-f10c-42b1-ab80-284125dd09f2">7.2</a></span><span class="Bold">)</span></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a1f9a367-fcfe-46e9-9ea5-8ce22108729d"></a><a name="section-5.8"></a><p></p>
<h2>5.8  Dosing</h2>
<p class="First">Patients should be advised to measure hydrocodone bitartrate and chlorpheniramine maleate oral solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions <span class="Italics">[see Overdosage </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0c062d2f-49ca-44f6-a30d-76824986a1bb"></a><a name="section-5.9"></a><p></p>
<h2>5.9  Coexisting Conditions</h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution should be used with caution in patients with thyroid disease, Addison’s disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1283bd6c-93ac-4217-af1e-2bc0fd7254b8"></a><a name="section-5.10"></a><p></p>
<h2>5.10  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Use in Specific Populations </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_ece0ac25-8b59-4f27-9721-f07e8655c78d">8.6</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_03f23e46-5e94-4c26-8fd6-233b4df78863"></a><a name="section-5.11"></a><p></p>
<h2>5.11  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Use in Specific Populations </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_ada8f944-eacd-4838-a32f-c2bceadaad81">8.7</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_eb8a0e30-63ca-4ced-84b8-8c5655f401dc"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Use of hydrocodone bitartrate, a semisynthetic opioid, may result in the following: </p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_58123411-0f53-420e-b00f-3638667874ad">5.1</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics"> and Overdosage </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug dependence</span> <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_8bda7078-e860-4780-b213-12ea2ac673fe">5.2</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_9347e0b3-f4e0-485f-8e37-6386926e46fe">5.3</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics"> and Overdosage </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">] </span>
</li>
<li>Decreased mental alertness with impaired mental and/or physical abilities <span class="Italics">[see Warnings and </span><span class="Italics">Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_496fdcbc-2473-4a5b-8561-245dfe45c09a">5.4</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span> <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_21855ad0-7043-4e5a-9840-91abf3930301">5.5</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">] </span>
</li>
</ul>
<p>Use of chlorpheniramine, an antihistamine, may result in:</p>
<ul class="Disk"><li>Decreased mental alertness with impaired mental and/or physical abilities <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_496fdcbc-2473-4a5b-8561-245dfe45c09a">5.4</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">] </span>
</li></ul>
<p>The following adverse reactions have been identified either during clinical trials of hydrocodone bitartrate and/or chlorpheniramine maleate or during their use post-approval. Because these reactions may be reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p>The most common adverse reactions of hydrocodone bitartrate and chlorpheniramine maleate oral solution include: Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>; blurred, double, or other <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, facial <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. </p>
<p>Other adverse reactions include: </p>
<p>Respiratory: Dryness of the pharynx and respiratory passages, occasional tightness of the chest, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, or troubled breathing. </p>
<p>Gastrointestinal System: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (more frequent in ambulatory than in recumbent patients), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, and/or loss of appetite. </p>
<p>Genitourinary System: Ureteral spasm, spasm of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> sphincters, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span>. </p>
<p>Dermatological System: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, excessive perspiration. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_5a356f49-8ad4-439a-927c-8ba01b943f01"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cf1ca2b1-a77b-44f6-b982-02872e9bbfb2"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</h2>
<p class="First">The use of opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants concomitantly with hydrocodone bitartrate and chlorpheniramine maleate oral solution may cause an additive CNS depressant effect and should be avoided. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_283b0d0f-f10c-42b1-ab80-284125dd09f2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 MAOIs and Tricyclic Antidepressants</h2>
<p class="First">Do not prescribe hydrocodone bitartrate and chlorpheniramine maleate oral solution if the patient is taking a prescription MAOI (i.e., certain drugs used for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_d22b5f39-568f-4f6d-b818-7f2a195ae08b">5.7</a></span></span></span><span class="Italics"><span class="Bold">)</span>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1538533e-2525-4407-8e5f-eae7ad77fc97"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticholinergic Drugs</h2>
<p class="First">Hydrocodone and chlorpheniramine should be administered cautiously to persons receiving other anticholinergic drugs in order to avoid <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and excessive anticholinergic effects. </p>
<p>Additive adverse effects resulting from cholinergic blockade (e.g., <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">xerostomia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>) may occur when anticholinergic drugs are administered with chlorpheniramine <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_0e960a6b-9598-4670-8585-ad95583a4642">5.6</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_6d478e21-8bed-4e78-829c-ae6efec2aa0a"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_3821ef22-961c-410a-a0d2-1900568edfd9"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects: </span>Pregnancy Category C </p>
<p>There are no adequate and well-controlled studies of hydrocodone bitartrate and chlorpheniramine maleate oral solution in pregnant women. Reproductive toxicity studies have not been conducted with hydrocodone bitartrate and chlorpheniramine maleate oral solution; however, studies are available with individual active ingredients or related active ingredients. Hydrocodone was teratogenic in hamsters. Codeine, an opiate related to hydrocodone, increased resorptions and decreased fetal weight in rats. A single retrospective study reported that chlorpheniramine was teratogenic in humans; however, the significance of these findings was not known. Developmental toxicity was also evident with chlorpheniramine in mice and rats. Because animal reproduction studies are not always predictive of human response, hydrocodone bitartrate and chlorpheniramine maleate oral solution should be used during pregnancy only if the benefit justifies the potential risk to the fetus. </p>
<p><span class="Underline">Hydrocodone: </span></p>
<p>Hydrocodone has been shown to be teratogenic in hamsters when given in a dose approximately 35 times the maximum recommended human daily dose (MRHDD) (on a mg/m<span class="Sup">2 </span>basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to hydrocodone. In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 50 times the MRHDD of hydrocodone (on a mg/m<span class="Sup">2 </span>basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity. In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 25 and 120 times, respectively, the MRHDD of hydrocodone (on a mg/m<span class="Sup">2 </span>basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects. </p>
<p><span class="Underline">Chlorpheniramine: </span></p>
<p>A retrospective study found a small, but statistically significant, association between maternal use of chlorpheniramine and <span class="product-label-link" type="condition" conceptid="4288544" conceptname="Inguinal hernia">inguinal hernia</span> and eye or ear anomalies in children. Other retrospective studies have found that the frequency of congenital anomalies, in general, was not increased among offspring of women who took chlorpheniramine during pregnancy. The significance of these findings to the therapeutic use of chlorpheniramine in human pregnancy is not known. </p>
<p>In studies with chlorpheniramine in which pregnant rats and rabbits were dosed throughout organogenesis, oral doses up to approximately 20 and 25 times the MRHDD on a mg/m<span class="Sup">2 </span>basis, respectively, produced no adverse developmental effects. However, when mice were dosed throughout pregnancy, a dose approximately 5 times the MRHDD (on a mg/m<span class="Sup">2 </span>basis at an oral dose of 20 mg/kg/day) was embryolethal, and postnatal survival was decreased when dosing was continued after parturition. Embryolethality was also observed when male and female rats were dosed with approximately 5 times the MRHDD (on a mg/m<span class="Sup">2 </span>basis at an oral dose of 10 mg/kg/day) prior to mating. </p>
<p><span class="Italics">Nonteratogenic Effects: </span>Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_064a9304-dfa4-4ab4-a016-5e6d2889b2f7"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">As with all opioids, administration of hydrocodone bitartrate and chlorpheniramine maleate oral solution to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_d2d43781-e0f7-4675-b04e-875848f1dcf0"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Caution should be exercised when hydrocodone bitartrate and chlorpheniramine maleate is administered to nursing mothers. Hydrocodone and chlorpheniramine are excreted in human milk. The clinical significance is unknown; however, the anticholinergic action of chlorpheniramine may suppress lactation if taken prior to nursing. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone bitartrate and chlorpheniramine maleate oral solution, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_f9b81963-404c-460a-8520-dda49e563fd9"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of hydrocodone bitartrate and chlorpheniramine maleate oral solution in pediatric patients under 18 years of age have not been established. The use of hydrocodone in children less than 6 years of age has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> <span class="Italics">[see Warnings and Precautions <span class="Bold">(<a href="#LINK_58123411-0f53-420e-b00f-3638667874ad">5.1</a></span><span class="Bold">)</span>]. </span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_e6bd1ee9-b6f8-406a-ab83-cfd8fe8560dd"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies have not been conducted with hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution. Other reported clinical experience with the individual active ingredients of hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The pseudoephedrine contained in hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ece0ac25-8b59-4f27-9721-f07e8655c78d"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution should be given with caution in patients with severe impairment of renal function. Pseudoephedrine is primarily excreted unchanged in the urine as unchanged drug with the remainder apparently being metabolized in the liver. Therefore, pseudoephedrine may accumulate in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ada8f944-eacd-4838-a32f-c2bceadaad81"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution should be given with caution in patients with severe impairment of hepatic function. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_c4b1b091-a3f1-4515-a694-2b5cef6694bf"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0ed5f9e3-ba38-4b2d-972c-d63f515a7dde"></a><a name="section-9.1"></a><p></p>
<h2>9.1  Controlled Substance</h2>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution is a Schedule II controlled prescription containing hydrocodone bitartrate and should be prescribed and administered with caution. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_251610c3-fcdb-4588-b05b-d5aa6d1c93fb"></a><a name="section-9.2"></a><p></p>
<h2>9.2  Abuse</h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of hydrocodone bitartrate and chlorpheniramine maleate oral solution, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b1188204-6e04-4c09-a4b1-d4c0b164e906"></a><a name="section-9.3"></a><p></p>
<h2>9.3  <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of opioids; therefore, hydrocodone bitartrate and chlorpheniramine maleate oral solution should be prescribed and administered with caution. </p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of opioid therapy. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No human overdosage data are available for hydrocodone bitartrate and pseudoephedrine hydrochloride oral solution. </p>
<p><span class="Underline">Hydrocodone</span>: </p>
<p>Overdosage with hydrocodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. </p>
<p><span class="Underline">Chlorpheniramine</span>: </p>
<p>Manifestations of chlorpheniramine overdosage may vary from central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to stimulation. Central toxic effects are characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, sedation, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Severe overdosage may produce <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, medullary <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Peripheral toxicity includes <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>, vasodilation, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, and diminished gastrointestinal motility. <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, pharynx, bronchi, and nasal passages may be observed. </p>
<p>Impaired secretion from sweat glands following toxic doses of drugs with anticholinergic side effects may predispose to <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>. </p>
<p>An adult ingested 400 mg chlorpheniramine with no reported serious adverse effects. Toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, a possible class effect from <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of sedating antihistamines, has been reported with accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of chlorpheniramine. </p>
<p>Treatment of overdosage consists of discontinuation of hydrocodone bitartrate and chlorpheniramine maleate oral solution together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to opioids including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug. </p>
<p>Hemodialysis is not routinely used to enhance the elimination of chlorpheniramine from the body. Urinary excretion of chlorpheniramine is increased when the pH of the urine is acidic; however, acid <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is NOT recommended to enhance elimination in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, as the risks of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidemia</span> and <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span> in patients with <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> far outweigh any potential benefit. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_fbac5b4a-b11d-470f-9e1b-b21e8685d2d1"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution contains hydrocodone bitartrate (a semisynthetic centrally-acting opioid antitussive) and chlorpheniramine maleate (an antihistamine). </p>
<p>Each 5 mL dose of hydrocodone bitartrate and chlorpheniramine maleate oral solution is supplied as a clear, colorless to light yellow, grape-flavored oral solution which contains: hydrocodone bitartrate, USP, 5 mg and chlorpheniramine maleate, USP, 4 mg. </p>
<p>Hydrocodone bitartrate and chlorpheniramine maleate oral solution is supplied as a clear, colorless to light yellow, grape-flavored solution.</p>
<p>The inactive ingredients for the oral solution are citric acid anhydrous, glycerin, grape flavor, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate, sodium saccharin, and sucrose. </p>
<p>Hydrocodone bitartrate is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-, [<span class="Italics">R-</span>(<span class="Italics">R*</span>,<span class="Italics">R*</span>)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5); also known as 4,5α-Epoxy-3-methoxy-17methylmorphinan-6-one tartrate (1:1) hydrate (2:5); a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine; and may be represented by the following structural formula: </p>
<p><img alt="Hydrocodone Bitartrate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=47dae0e8-065f-4722-a1c1-4763e25e14d4&amp;name=hydrocodone-bitartrate-and-chlorpheniramine-maleat-1.jpg"> </p>
<p>Hydrocodone Bitartrate</p>
<p>C<span class="Sub">18</span>H<span class="Sub">21</span>NO<span class="Sub">3 </span>? C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">6 </span>? 2.5 H<span class="Sub">2</span>O</p>
<p>Molecular weight = 494.5</p>
<p>Chlorpheniramine maleate is 2-pyridinepropanamine, γ-(4-chlorophenyl)-<span class="Italics">N</span>,<span class="Italics">N</span>-dimethyl-, (<span class="Italics">Z</span>)-2- butenedioate (1:1) and has the following chemical structure:  </p>
<p><img alt="Chlorpheniramine Maleate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=47dae0e8-065f-4722-a1c1-4763e25e14d4&amp;name=hydrocodone-bitartrate-and-chlorpheniramine-maleat-2.jpg"> </p>
<p> Chlorpheniramine Maleate</p>
<p>C<span class="Sub">16</span>H<span class="Sub">19</span>ClN<span class="Sub">2</span> ? C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span></p>
<p>Molecular weight = 390.86</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_fbc62e38-7f9b-4ecb-9bdb-56ff69dbb556"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_d8ba8f10-0a97-4bd9-9f98-1bf4a761b927"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center. In excessive doses, hydrocodone will depress respiration. Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, and physical and physiological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. </p>
<p>Chlorpheniramine is an antihistamine drug (H<span class="Sub">1</span> receptor antagonist) that also possesses anticholinergic and sedative activity. It prevents released histamine from dilating capillaries and causing <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the respiratory mucosa.  </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_f00e677a-3f2a-4b1c-a978-5a8a2288cb5d"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of hydrocodone bitartrate and chlorpheniramine maleate after single dose administration of  5 mL hydrocodone bitartrate and chlorpheniramine maleate oral solution are equivalent to respective reference solutions of 5 mL hydrocodone bitartrate (5 mg/5 mL), and 5 mL chlorpheniramine maleate (4 mg/5 mL). </p>
<p>Hydrocodone had mean (SD) peak plasma concentration of 10.6 (2.63) ng/mL at 1.4 (0.55) hours. The mean plasma half-life of hydrocodone is approximately 4.9 hours. Chlorpheniramine had a mean (SD) plasma peak concentration of 7.20 (1.98) ng/mL at 3.5 (1.6) hours. The mean plasma half-life of chlorpheniramine is approximately 24 hours. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_821138c3-0a53-438c-b5f7-50bd650acedc"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_8292fa9d-3d67-4727-b82b-a633f7a37ddd"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First">Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with hydrocodone bitartrate and chlorpheniramine maleate oral solution; however, published information is available for the individual active ingredients or related active ingredients. </p>
<p><span class="Underline">Hydrocodone: </span></p>
<p>Carcinogenicity studies were conducted with codeine, an opiate related to hydrocodone. In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 30 and 80 times, respectively, the MRHDD of hydrocodone on a mg/m<span class="Sup">2 </span>basis). </p>
<p><span class="Underline">Chlorpheniramine: </span></p>
<p>In 2 year studies in F344/N rats and B6C3F1 mice, chlorpheniramine maleate showed no evidence of tumorigenicity when administered 5 days/week at oral doses up to 30 and 50 mg/kg/day, respectively (approximately 15 times the MRHDD on a mg/m<span class="Sup">2 </span>basis). </p>
<p>Chlorpheniramine maleate was not mutagenic in the <span class="Italics">in vitro</span> bacterial reverse mutation assay or the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay. Chlorpheniramine maleate was clastogenic in the <span class="Italics">in vitro</span> CHO cell chromosomal aberration assay. </p>
<p> Chlorpheniramine maleate had no effects on fertility in rats and rabbits at oral doses approximately 20 and 25 times the MRHDD on a mg/m<span class="Sup">2 </span>basis, respectively. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_060e3431-b303-4127-930c-a649f0c64ea0"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Efficacy studies were not conducted with hydrocodone bitartrate and chlorpheniramine maleate oral solution. Efficacy of hydrocodone bitartrate and chlorpheniramine maleate oral solution is based on demonstration of bioequivalence to the individual reference products <span class="Italics">[see Clinical Pharmacology <span class="Bold">(<a href="#LINK_f00e677a-3f2a-4b1c-a978-5a8a2288cb5d">12.3</a></span><span class="Bold">)</span>]</span>. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_0ef6a488-e212-44dd-be41-742b14459d17"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED</h1>
<p class="First">Hydrocodone bitartrate and chlorpheniramine maleate oral solution is supplied as a clear, colorless to light yellow, grape-flavored solution containing 5 mg of hydrocodone bitartrate and 4 mg of chlorpheniramine maleate in each 5 mL. It is available in bottles of 16 fluid ounces (473 mL) NDC 27808-104-01.</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_0d862fa7-dbc0-4fd1-ab75-40a5c1729a60"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b9af8056-11ae-4459-bae9-f1f3cd2ec996"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Overdosage</h2>
<p class="First">Patients should be advised not to increase the dose or dosing frequency of hydrocodone bitartrate and chlorpheniramine maleate oral solution because serious adverse events such as <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may occur with overdosage <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_58123411-0f53-420e-b00f-3638667874ad">5.1</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">; Overdosage <span class="Bold">(<a href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</a></span><span class="Bold">)</span>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d741f5bc-8477-4386-b842-d3a4e4cb1509"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Dosing</h2>
<p class="First">Patients should be advised to measure hydrocodone bitartrate and chlorpheniramine maleate oral solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_305230d0-9579-4194-b195-5c61976f70f6">5.8</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b46c61d1-2283-4e51-9880-9e036049e397"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Concomitant Use of Alcohol and Other Central Nervous System Depressants</h2>
<p class="First">Patients should be advised to avoid the use of alcohol and other central nervous system depressants while taking hydrocodone bitartrate and chlorpheniramine maleate oral solution because additional reduction in mental alertness may occur <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_496fdcbc-2473-4a5b-8561-245dfe45c09a">5.4</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0ef1b77e-f902-4b26-bd90-206947f11f69"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Activities Requiring Mental Alertness</h2>
<p class="First">Patients should be advised to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as hydrocodone bitartrate and chlorpheniramine maleate oral solution may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> <span class="Italics">[see Warnings and Precautions <span class="Bold">(<a href="#LINK_496fdcbc-2473-4a5b-8561-245dfe45c09a">5.4</a></span><span class="Bold">)</span>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7d09dcd6-6d49-4b91-9f05-9287262285bc"></a><a name="section-16.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></h2>
<p class="First">Patients should be cautioned that hydrocodone bitartrate and chlorpheniramine maleate oral solution contains hydrocodone bitartrate and can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_8bda7078-e860-4780-b213-12ea2ac673fe">5.2</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7c78747-cda4-4a6a-affd-66ad14b73926"></a><a name="section-16.6"></a><p></p>
<h2>17.6 MAOIs</h2>
<p class="First">Patients should be informed that they should not use hydrocodone bitartrate and chlorpheniramine maleate oral solution with a MAOI or within 14 days of stopping use of an MAOI <span class="Italics">[see Warnings and Precautions </span><span class="Bold"><span class="Italics">(<span class="Italics"><a href="#LINK_d22b5f39-568f-4f6d-b818-7f2a195ae08b">5.7</a></span></span></span><span class="Bold"><span class="Italics">)</span></span><span class="Italics">]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_b1a26aac-a7a0-4147-8315-d939e5e319e4"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><img alt="Bottle of 16 fl. oz. (473 mL)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=47dae0e8-065f-4722-a1c1-4763e25e14d4&amp;name=hydrocodone-bitartrate-and-chlorpheniramine-maleat-3.jpg"> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE 		
					SOLUTION</strong><br><span class="contentTableReg">hydrocodone bitartrate and chlorpheniramine maleate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:27808-104</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCODONE BITARTRATE</strong> (HYDROCODONE) </td>
<td class="formItem">HYDROCODONE BITARTRATE</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CHLORPHENIRAMINE MALEATE</strong> (CHLORPHENIRAMINE) </td>
<td class="formItem">CHLORPHENIRAMINE MALEATE</td>
<td class="formItem">4 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GRAPE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (colorless to light) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">GRAPE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:27808-104-01</td>
<td class="formItem">473 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA206438</td>
<td class="formItem">03/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Tris Pharma Inc
							(947472119)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Tris Pharma Inc</td>
<td class="formItem"></td>
<td class="formItem">947472119</td>
<td class="formItem">ANALYSIS(27808-104), MANUFACTURE(27808-104)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a453de2a-b56d-4fc7-8bf6-5568f21bf6d8</div>
<div>Set id: 47dae0e8-065f-4722-a1c1-4763e25e14d4</div>
<div>Version: 3</div>
<div>Effective Time: 20150226</div>
</div>
</div> <div class="DistributorName">Tris Pharma Inc</div></p>
</body></html>
